Trial · NCT02406209
A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
NCT02406209, Phase 2, Completed, Aldeyra Therapeutics, Inc.; results first posted 2023-03-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis. Trials, record NCT02406209. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02406209
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
- NCT number
- NCT02406209
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 45 participants, actual
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- NS2, Prednisolone acetate ophthalmic suspension (1%)
- First posted
- 2015-04-02
- Last updated
- 2023-03-27
- Results first posted
- 2023-03-27
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Anterior Chamber Cell Grade at Week 8 | The efficacy assessment period was assessed at Week 8; baseline was Day 1. | Change from baseline comparison of NS2 ophthalmic drops (0.5%), NS2 (0.5%) and Pred Forte® (0.1%) ophthalmic drops, and Pred Forte® (1%) ophthalmic drops on an anterior chamber cell grade scale of 0 to 4 (0 = absent, 4 = severe). The least squares mean (standard error) was derived from analysis of covariance (ANCOVA) with baseline as a covariate and treatment group as a factor. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Anterior Chamber Cell Grade at Week 8 | The efficacy assessment period was assessed at Week 8; baseline was Day 1. | Modified intent-to-treat | units on a scale | LEAST_SQUARES_MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Anterior Chamber Cell Grade at Week 8 | NS2 Ophthalmic Drops (0.5%) | -0.7 | Standard Error 0.31 | units on a scale | |
| Anterior Chamber Cell Grade at Week 8 | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | -0.9 | Standard Error 0.29 | units on a scale | |
| Anterior Chamber Cell Grade at Week 8 | Pred Forte® (1%) Ophthalmic Drops | -0.5 | Standard Error 0.32 | units on a scale |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | NS2 Ophthalmic Drops (0.5%) | 15 | |
| Overall Study | STARTED | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 16 | |
| Overall Study | STARTED | Pred Forte® (1%) Ophthalmic Drops | 14 | |
| Overall Study | COMPLETED | NS2 Ophthalmic Drops (0.5%) | 7 | |
| Overall Study | COMPLETED | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 7 | |
| Overall Study | COMPLETED | Pred Forte® (1%) Ophthalmic Drops | 6 | |
| Overall Study | NOT COMPLETED | NS2 Ophthalmic Drops (0.5%) | 8 | |
| Overall Study | NOT COMPLETED | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 9 | |
| Overall Study | NOT COMPLETED | Pred Forte® (1%) Ophthalmic Drops | 8 |
Source ClinicalTrials.gov
Adverse events81
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Iridocyclitis | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 0 | 15 | |
| other | Iridocyclitis | Eye disorders | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 1 | 16 | |
| other | Iridocyclitis | Eye disorders | Pred Forte® (1%) Ophthalmic Drops | 1 | 14 | |
| other | Conjunctival haemorrhage | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 0 | 15 | |
| other | Conjunctival haemorrhage | Eye disorders | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 1 | 16 | |
| other | Conjunctival haemorrhage | Eye disorders | Pred Forte® (1%) Ophthalmic Drops | 0 | 14 | |
| other | Cystoid macular oedema | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 0 | 15 | |
| other | Cystoid macular oedema | Eye disorders | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 1 | 16 | |
| other | Cystoid macular oedema | Eye disorders | Pred Forte® (1%) Ophthalmic Drops | 0 | 14 | |
| other | Eye inflammation | Eye disorders | NS2 Ophthalmic Drops (0.5%) | 0 | 15 |
1 to 10 of 81Source ClinicalTrials.gov
See all 81 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | NS2 Ophthalmic Drops (0.5%) | 0 | 15 |
| Total, all-cause mortality | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 0 | 16 |
| Total, all-cause mortality | Pred Forte® (1%) Ophthalmic Drops | 0 | 14 |
| Total, other adverse events | NS2 Ophthalmic Drops (0.5%) | 8 | 15 |
| Total, other adverse events | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 8 | 16 |
| Total, other adverse events | Pred Forte® (1%) Ophthalmic Drops | 3 | 14 |
| Total, serious adverse events | NS2 Ophthalmic Drops (0.5%) | 0 | 15 |
| Total, serious adverse events | NS2 (0.5%) and Pred Forte® (0.1%) Ophthalmic Drops | 0 | 16 |
| Total, serious adverse events | Pred Forte® (1%) Ophthalmic Drops | 0 | 14 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32955967 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02406209
GET https://conductscience.org/api/trials/v1/NCT02406209/events?page=2